This conference is themed “Innovative Processes, Achieving the Future of the Pharmaceutical Industry,” featuring one keynote session and three parallel sessions, gathering over 50 professional speakers from the fields of antibodies, ADCs, GLP-1, and peptides. It focuses on downstream processes and advanced separation and purification techniques, discussing the future of the pharmaceutical industry! Known as … Read more
Patients with cholangiocarcinoma (BTC) have a very poor prognosis. In recent years, both the incidence and mortality rates have shown a continuous upward trend. BTC mainly includes gallbladder cancer (GBC) and cholangiocarcinoma (CCA), which can be broadly divided into two subtypes: intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC). It is well known that clarifying the … Read more
Editor’s Note On May 11, at the 18th Gastric Cancer Academic Conference (CGCC 2024), Professor Ying Jie’Er from Zhejiang Provincial Cancer Hospital delivered an academic report titled “Treatment of Elderly Patients with Advanced Gastric Cancer”. The content is organized as follows for readers. 1. Epidemiology and Prognosis of Elderly Patients with Advanced Gastric Cancer According … Read more
Since the concept of ADC was proposed in 1900, it has existed as a new type of cancer treatment method. Although its development has faced many challenges over the past century, top scientists in the relevant fields around the world have been conducting years of experiments and iterations to improve safety, reduce off-target effects, and … Read more
Antibody-drug conjugates (ADCs) consist of linker, payload, and monoclonal antibodies (mAb). They combine the advantages of high specificity targeting ability and potent cytotoxic effects, achieving precise and efficient destruction of cancer cells, making them one of the hot topics in anticancer drug development.Since the first ADC drug Mylotarg® (gemtuzumab ozogamicin) was approved by the FDA … Read more
Click below to follow and never miss cancer knowledge~ Author: Guo Lin When it comes to cancer treatment, chemotherapy, surgery, and radiotherapy are the most familiar traditional methods. However, with the advancement of anti-cancer technology, a new type of “smart” anti-cancer drug that combines the advantages of chemotherapy and targeted drugs—Antibody Drug Conjugates (ADC)—has gradually … Read more
Follow below to not miss cancer knowledge~ 1 Three Major Therapies for Lung Cancer Have Shortcomings, Urgent Need for Innovative Drugs In recent years, significant progress has been made in the treatment of advanced non-small cell lung cancer, with a growing variety of therapeutic drugs leading to a triad of targeted, immunotherapy, and chemotherapy. Targeted … Read more
Intrahepatic cholangiocarcinoma (ICC) originates from the epithelial cells of the intrahepatic bile ducts. Among primary liver malignancies, the incidence of ICC is second only to hepatocellular carcinoma, accounting for 10% to 15% of primary liver cancer. Recommended Suggestions 1) It is recommended to use a combination regimen of gemcitabine and platinum-based drugs, and if conditions … Read more
Introduction Antibody-drug conjugates (ADCs) are composed of monoclonal antibodies targeting specific antigens linked to small molecule cytotoxic drugs via linkers. They combine the strong killing effect of traditional small molecule chemotherapy with the tumor-targeting ability of antibody drugs. ADCs consist of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, the … Read more
Immunotherapy has revolutionized cancer treatment by mobilizing the body’s immune system to eliminate tumors. However, despite significant clinical success in certain types of liquid tumors, the efficacy of immunotherapy remains poor in most solid tumors. The tumor immune microenvironment (TIME) is complex and heterogeneous, with various immune components interacting, which is a major reason affecting … Read more